Navigation Links
Dey L.P. and Critical Therapeutics Launch Twice-Daily ZYFLO CR(TM) (Zileuton) Extended-Release Tablets for the Chronic Treatment of Asthma
Date:9/27/2007

First twice-daily leukotriene synthesis inhibitor provides additional

treatment option for asthma patients not fully controlled on other

medications

NAPA, Calif., Sept. 27 /PRNewswire-FirstCall/ -- Dey, L.P., an affiliate of Merck KGaA of Darmstadt, Germany, announced today that it has launched ZYFLO CR(TM) (zileuton) extended-release tablets with its marketing partner, Critical Therapeutics, Inc. (Nasdaq: CRTX). ZYFLO CR(TM) offers twice-daily, extended-release dosing for the prevention and chronic treatment of asthma in patients 12 years of age and older.

"We are excited to partner with Critical Therapeutics to bring a twice-daily formulation of ZYFLO(R) (zileuton tablets) to the many patients affected by chronic asthma," said Christy Taylor, Executive Vice President, Sales, Marketing and Business Development at DEY. "Our collaboration with Critical Therapeutics and the launch of ZYFLO CR(TM) demonstrate our commitment to developing and marketing innovative respiratory therapeutics to enhance patients' lives."

In March 2007, Critical Therapeutics and DEY entered into an agreement for the co-promotion of ZYFLO CR(TM) and ZYFLO(R), the immediate-release formulation of zileuton. DEY's sales force began promoting ZYFLO(R) on April 30, 2007. ZYFLO CR(TM) received approval from the U.S. Food and Drug Administration on May 31, 2007.

About ZYFLO CR and ZYFLO

ZYFLO CR(TM) and ZYFLO(R) (zileuton tablets) are the only FDA-approved leukotriene synthesis inhibitors for the prophylaxis and chronic treatment of asthma in adults and children 12 years of age and older. ZYFLO CR(TM) and ZYFLO(R) are not indicated for use in the reversal of bronchospasm in acute asthma attacks, but can be continued during acute exacerbations of asthma. Leukotrienes are inflammatory mediators in asthma that can trigger asthma symptoms, including inflammation, swelling, bronchoconstriction and mucus secretion. ZYFLO CR(TM) uses SkyePharma PLC's (LSE: SKP) proprietary Geomatrix(R) drug delivery technology, which controls the amount and rate of drug released into the body.

The recommended dose of ZYFLO CR(TM) is two 600 mg extended-release tablets twice daily, within one hour after morning and evening meals, for a total daily dose of 2400 mg. The recommended dose of ZYFLO(R) is one 600 mg immediate-release tablet four times a day for a total daily dose of 2400 mg.

ZYFLO CR(TM) and ZYFLO(R) are contraindicated in patients with active liver disease or transaminase elevations greater than or equal to three times the upper limit of normal. A small percentage of patients treated with ZYFLO CR(TM) (2.5%) and ZYFLO(R) (1.9%) in placebo-controlled trials showed an increased release of a liver enzyme known as ALT and bilirubin (an orange or yellowish pigment in bile). As a result, the level of liver enzymes in patients treated with ZYFLO CR(TM) and ZYFLO(R) should be measured by a simple blood test. It is recommended that physicians perform this test before administering ZYFLO CR(TM) and ZYFLO(R) and repeat the test on a regular basis while patients are on the medication. Patients taking ZYFLO CR(TM) and theophylline should reduce the theophylline dose by 50%. Patients taking ZYFLO CR(TM) and propranolol or warfarin should be monitored and doses adjusted as appropriate. Most common side effects associated with the use of ZYFLO CR(TM) and ZYFLO(R) are sinusitis, nausea and pharyngolaryngeal pain and abdominal pain, upset stomach and nausea, respectively.

For full prescribing information for ZYFLO CR(TM), please visit http://www.zyflocr.com or call the Company's toll free telephone number 1-866-835-8216 to request medical information.

For full prescribing information for ZYFLO(R), please visit http://www.zyflo.com or call the Company's toll free telephone number 1-866-835-8216 to request medical information.

About Dey, L.P.

Dey, L.P. is a specialty pharmaceutical company focused on the development, manufacturing and marketing of prescription drug products for the treatment of respiratory diseases, respiratory-related allergies, and emergency care medicine. As the US leader in nebulized respiratory medication, DEY puts patients first through its development of innovative and affordable therapies. The Web sites for DEY include http://www.dey.com, http://www.accuneb.com, http://www.curosurfusa.com, http://www.cyanokit.com, http://www.duoneb.com, http://www.epipen.com and http://www.perforomist.com. Dey, L.P. is an affiliate of Merck KGaA, Darmstadt, Germany.

ZYFLO is a registered trademark of Critical Therapeutics, Inc.

ZYFLO CR is a trademark of Critical Therapeutics, Inc.

GEOMATRIX is a registered trademark of SkyePharma PLC.

Media contacts: Dey, L.P. Media Line

1-800-755-5560 ext. 8363

or

Harriet Ullman

Feinstein Kean Healthcare

617-761-6776

hullman@fkhealth.com


'/>"/>
SOURCE Dey, L.P.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Critical factors for successful microarray and real-time PCR analyses
2. MicroRNA Profiling by Array Analysis Reveals Critical BioMarkers
3. Chicago-Milwaukee "mega-metro" infrastructure improvements are critical
4. Caden Biosciences may signal critical mass
5. IT critical in pandemic response, but many are not paying attention
6. IT is critical for economic growth, says UW business dean
7. JohnLets Get Serious - Manufacturing is a critical part of the Wisconsin economy
8. Diamond Film May Enable Critical New Sensors For Bioterror
9. Canadian firm buys Proventiv Therapeutics, makes ex-Bone Care exec CEO
10. Merge launches diagnostic mammography workstation in Europe
11. Einstein Wireless launches cellular alert system
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... , Feb. 5, 2016  In the pharmaceutical ... for a host of launch activities including the identification ... this launch activity is especially high in the oncology ... Best Practices and the Role of Medical Affairs ... companies focused on oncology therapies find better ways to ...
(Date:2/5/2016)... , Feb. 5, 2016 Australian-US drug discovery and ... today the appointment of a new Chairman, Mr John ... , effective immediately. James Garner , has ... Director and former Acting CEO, Mr Iain Ross , ... Director. --> James Garner , has also been ...
(Date:2/4/2016)... -- Sangamo BioSciences, Inc. (NASDAQ: SGMO ), the leader ... Lanphier , Sangamo,s president and chief executive officer, will ... Therapeutic ® development programs and an overview of ... Thursday, February 11, 2016, at the Leerink Partners 5 ... being held in New York . ...
(Date:2/4/2016)... China , Feb. 4, 2016 Beike ... and various medical institutions attended a ceremony in late ... integrative, personalized cell therapy in 2016. ... "Shenzhen Clinical Translation Platform for Personalized Cell Therapy" was ... Regional Cell Production Center, both subsidiaries of Beike Biotechnology ...
Breaking Biology Technology:
(Date:2/3/2016)... 2016 --> ... "Automated Fingerprint Identification System Market by Component (Hardware and ... & Finance, Government, Healthcare, and Transportation) and Geography - ... is expected to be worth USD 8.49 Billion by ... and 2020. The transformation and technology evolution from the ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 /PRNewswire/ ... Potentials of that Rising Market Are you ... new analysis forecasts revenues for checkpoint inhibitors. Visiongain,s ... world market, submarket, product and national level. ... Instead discover what progress, opportunities and revenues those ...
(Date:2/1/2016)... , Feb. 1, 2016  Today, the first ... (AHA) announced plans to develop a first of its ... power of IBM Watson. In the first application of ... IBM (NYSE: IBM ), and Welltok will create ... health assessments with cognitive analytics, delivered on Welltok,s health ...
Breaking Biology News(10 mins):